Left Bundle Branch Pacing for Cardiac Resynchronization Therapy: Nonrandomized On-Treatment Comparison With His Bundle Pacing and Biventricular Pacing

医学 射血分数 心脏病学 内科学 心脏再同步化治疗 捆绑 心脏起搏 心室起搏 心力衰竭 材料科学 复合材料
作者
Shengjie Wu,Lan Su,Pugazhendhi Vijayaraman,Rujie Zheng,Mengxing Cai,Lei Xu,Ruiyu Shi,Zhouqing Huang,Zachary I. Whinnett,Weijian Huang
出处
期刊:Canadian Journal of Cardiology [Elsevier BV]
卷期号:37 (2): 319-328 被引量:236
标识
DOI:10.1016/j.cjca.2020.04.037
摘要

Background Left bundle branch pacing (LBBP) is a novel method for delivering cardiac resynchronization therapy (CRT). We compared on-treatment outcomes with His bundle pacing (HBP) and biventricular pacing (BVP) in this nonrandomized observational study. Methods Consecutive patients with left-ventricular ejection fraction (LVEF) ≤ 40% and typical left bundle branch block (LBBB) referred for CRT received BVP, HBP, or LBBP. QRS duration, pacing threshold, LVEF, and New York Heart Association (NYHA) class were assessed. Results One hundred thirty-seven patients were recruited: 49 HBP, 32 LBBP, and 54 BVP; 2 did not receive CRT. The majority of patients had nonischemic cardiomyopathy. Mean paced QRS duration was 100.7 ± 15.3 ms, 110.8 ± 11.1 ms, and 135.4 ± 20.2 ms during HBP, LBBP, and BVP, respectively. HBP and LBBP demonstrated a similar absolute increase (Δ) in LVEF (+23.9% vs +24%, P = 0.977) and rate of normalized final LVEF (74.4% vs 70.0%, P = 0.881) at 1-year follow-up. This was significantly higher than in the BVP group (Δ LVEF +16.7% and 44.9% rate of normalized final LVEF, P < 0.005). HBP and LBBP also demonstrated greater improvements in NYHA class compared with BVP. LBBP was associated with higher R-wave amplitude (11.2 ± 5.1 mV vs 3.8 ± 1.9 mV, P < 0.001) and lower pacing threshold (0.49 ± 0.13 V/0.5 ms vs 1.35 ± 0.73 V/0.5 ms, P < 0.001) compared with HBP. Conclusion LBBP appears to be a promising method for delivering CRT. We observed similar improvements in symptoms and LV function with LBBP and HBP. These improvements were significantly greater than those seen in patients treated with BVP in this nonrandomized study. These promising findings justify further investigation with randomized trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
现代苑博完成签到 ,获得积分10
1秒前
1秒前
chloe777完成签到,获得积分10
2秒前
hjh发布了新的文献求助10
2秒前
汉堡大王发布了新的文献求助10
2秒前
3秒前
3秒前
3秒前
李爱国应助Yi采纳,获得10
4秒前
所所应助炙热的彤采纳,获得10
5秒前
lb001完成签到 ,获得积分10
5秒前
meizu发布了新的文献求助10
6秒前
6秒前
英勇的奇异果关注了科研通微信公众号
6秒前
7秒前
籽籽完成签到,获得积分10
7秒前
susuq5发布了新的文献求助10
8秒前
Superxx发布了新的文献求助10
8秒前
chruse发布了新的文献求助20
9秒前
xiangjun完成签到,获得积分10
9秒前
10秒前
Copyright应助phyzb采纳,获得10
10秒前
乐乐应助凤梨罐头采纳,获得30
12秒前
wangxi发布了新的文献求助10
12秒前
13秒前
核桃应助科研通管家采纳,获得10
13秒前
是氓呀发布了新的文献求助10
13秒前
核桃应助科研通管家采纳,获得10
13秒前
CipherSage应助科研通管家采纳,获得10
14秒前
核桃应助科研通管家采纳,获得10
14秒前
14秒前
核桃应助科研通管家采纳,获得10
14秒前
15秒前
77发布了新的文献求助10
15秒前
Lucas应助科研通管家采纳,获得10
15秒前
15秒前
16秒前
16秒前
16秒前
meizu完成签到,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
REAL-WORLD EFFICACY AND GENOMIC LANDSCAPE OF POLATUZUMA VEDOTIN-BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A FOCUS ON TP53 MUTATIONS AND TREATMENT RESPONSE 500
Handbook of Luminescence Dating 500
Safety Pharmacology 500
《KNN基无铅压电陶瓷电学性能优化与物理机理研究》 500
Elgar Concise Encyclopedia of Space Law 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 计算机科学 化学工程 生物化学 物理 内科学 复合材料 催化作用 光电子学 物理化学 电极 细胞生物学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6943574
求助须知:如何正确求助?哪些是违规求助? 8629157
关于积分的说明 18304229
捐赠科研通 6378201
什么是DOI,文献DOI怎么找? 3079022
关于科研通互助平台的介绍 2119539
邀请新用户注册赠送积分活动 2055894